Evidence map›Paper›PMID 21107280›Full record

ArticleJournal of cardiovascular pharmacology2011

Selective enhancement of contractions to α1-adrenergic receptor activation in the aorta of mice with sickle cell disease.

Ramiro Juncos, Luis Juncos, Robert P Hebbel, Gregory M Vercellotti, Zvonimir S Katusic, Karl A Nath

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of cardiovascular pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Endothelin receptor antagonism in sickle cell disease: Is the time now?Canadian journal of physiology and pharmacology · 2026
    Review
  2. Article
  3. Vasculature and kidney complications in sickle cell disease.Journal of the American Society of Nephrology : JASN · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ramiro JuncosDivision of Nephrology and Hypertension, Mayo Clinic, Guggenheim 542, 200 First St., SW Rochester, MN 55905, USA.
Luis Juncos
Robert P Hebbel
Gregory M Vercellotti
Zvonimir S Katusic
Karl A Nath
Mayo Clinic · USPalmetto Hematology Oncology · USUniversity of Minnesota · US

Funding

VASCULAR PATHOBIOLOGY OF SICKLE CELL DISEASEP01HL055552 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HEBBEL, ROBERT P · 1995 to 2011
$17.3M
NHLBI NIH HHS HL55552NHLBI NIH HHS P01 HL055552
6 · The paper itself

Abstract

Sickle cell disease (SCD), the most common inherited hematologic disorder in the United States and the most common single gene disorder in the world, causes substantial morbidity and mortality. The major pathobiologic processes that underlie SCD include vaso-occlusion, inflammation, procoagulant processes, hemolysis, and altered vascular reactivity. The present study examined the vasoactive response to a-adrenergic activation in a murine model of SCD. Isolated aortas from sickle mice as compared with wild-type mice exhibit heightened contractions to norepinephrine and phenylephrine; such responses were completely blocked by an a1-receptor antagonist, prazosin. Aortas from either group exhibited comparable contractile responses to potassium chloride and the thromboxane agonist U46619 and no contractile response to an a2-adrenergic receptor agonist, UK14304. We conclude that there is an exaggerated vasoconstrictive response to a1-receptor agonists in SCD. Because sickle crisis is induced by diverse forms of stress, the latter attended by increased adrenergic activity, our findings may be relevant to the occurrence of sickle crisis. We also suggest that such heightened reactivity may contribute to vaso-occlusive processes that underlie ischemic injury in SCD. Finally, our findings urge caution in the use of phenylephrine in patients with SCD.

Indexed as

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidAnemia, Sickle CellAnimalsAortaFemaleMaleMiceMice, Inbred C57BLMice, TransgenicReceptors, Adrenergic, alpha-1Up-RegulationVasoconstriction15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidReceptors, Adrenergic, alpha-1

Identifiers

PMID21107280
PMCPMC3131975
OpenAlexW2086629322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.